Every 10-Q that Herbalife Ltd. (HLF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HLF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HLF filings page.
Herbalife Ltd. reported Q2 2026 net sales of $1,326.8 million, up from $1,259.1 million a year earlier, but recorded a net loss attributable to Herbalife of $26.3 million versus income of $49.3 million. Results included a $94.6 million loss on extinguishment of debt related to refinancing its credit facility and 12.250% senior secured notes due 2029, while interest expense declined to $37.4 million from $53.6 million.
For the first half of 2026, net sales were $2,644.0 million and net income attributable to Herbalife was $35.6 million, down from $99.7 million in the prior-year period, while net cash provided by operating activities increased to $146.7 million from $96.2 million. As of June 30, 2026, total assets were $2,857.7 million, total debt was $2,015.7 million, and total shareholders’ deficit was $466.9 million, with 104.8 million common shares outstanding.
Strategically, Herbalife completed the acquisition of Bioniq’s personalized nutrition business with preliminary consideration of $54.2 million, including contingent consideration with up to $95.0 million of additional milestone payments possible, and expanded its Pro2col Software venture, where Cristiano Ronaldo’s entity now owns 10% after purchasing an additional 5% for $7.5 million and providing services and sponsorship rights, and holds options to acquire up to a further 10%.
Herbalife Ltd. reported stronger results for the three months ended March 31, 2026. Net sales reached $1,317.2 million, up from $1,221.7 million a year earlier, while net income attributable to Herbalife rose to $61.9 million from $50.4 million.
Basic earnings per share were $0.60 versus $0.50, and diluted earnings per share were $0.57 versus $0.49. Operating cash flow improved sharply to $113.8 million from $0.2 million, helping lift cash and cash equivalents to $451.2 million. Total assets were $2,875.2 million against total liabilities of $3,309.4 million, leaving a shareholders’ deficit of $434.2 million, though this deficit narrowed year over year.
Debt remained high, with long-term debt of $1,981.9 million and total interest expense of $49.5 million, slightly lower than the prior year. India and Mexico delivered notable sales contributions, and the company booked $5.5 million of government grant income in China, reported as other operating income.
Herbalife Ltd. filed its Q3 2025 10-Q, showing modest top-line growth and stronger year-to-date profitability. Net sales were $1,273.7 million versus $1,240.3 million a year ago. Operating income was $125.8 million, and net income attributable to Herbalife was $43.2 million, or diluted EPS of $0.42.
For the first nine months, net sales were $3,754.5 million versus $3,785.7 million, while operating income rose to $381.2 million and net income to $142.9 million, reflecting lower SG&A and stable gross margins. Cash from operations reached $235.0 million. Cash and cash equivalents were $305.5 million, and inventories were $512.5 million. Long-term debt was $1,997.2 million, and the company reported compliance with covenants under its 2024 Credit Facility.
Herbalife completed asset acquisitions related to Pruvit and Pro2col for $19 million, with additional contingent payments tied to performance milestones, and acquired 51% of Link BioSciences for $6.5 million cash. Shareholders’ deficit improved to $606.0 million. Common shares outstanding were 103,310,720 as of October 29, 2025.